Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial

Journal of Bone and Mineral Research

Volumn 15, Issue 5, 2000, Pages 944-951

  Lane, Nancy E ^a,b   Sanchez, Sarah ^a   Modin, Gunnar W ^a   Genant, Harry K ^a   Pierini, Elena ^a   Arnaud, Claude D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Division of Rheumatology   (United States)

Author keywords

Glucocorticoid induced osteoporosis; Parathyroid hormone; Treatment

Indexed keywords

GLUCOCORTICOID; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BONE MASS; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034054290     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2000.15.5.944     Document Type: Article

References (24)

1. Lukert BP, Raisz, LG 1990 Glucocorticoid-osteoporosis: Pathogenesis and management. Ann Intern Med 112:352-364.
2. Adachi JD, Benson W G, Hodsman AB 1993 Glucocorticoid-osteoporosis. Semin Arthritis Rheum 23:375-384.
3. Dempster DW, Arlot MA, Menuier PJ 1983 Mean wall thickness and formation periods of trabecular bone packets in glucocorticoid-osteoporosis. Calcif Tissue Int 35:410-417.
4. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM 1996 Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose glucocorticoid in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 125:961-968.
5. Hall GM, Daniels M, Doyle DV, Spector TD 1994 Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 37:1499-1505.
6. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA 1997 Intermittent etidronate therapy to prevent glucocorticoid-induced osteoporosis. N Engl J Med 337:382-387.
7. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J 1993 Prevention of glucocorticoid osteoporosis: A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747-1753.
8. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Diafotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-osteoporosis. N Engl J Med 339:292-299.
9. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of the effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 350:550-555.
10. Reeve J, Bradbeer JN, Arlot, Davies UM, Green JR, Hampton L, Edoua C, Hesp R, Hulme P, Ashby JP 1991 hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic, and histological responses. Osteoporos Int 1:162-170.
11. Neer R, Slovik DM, Daly N, Potts JTJ, Nussbaum SR 1993 Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. Osteoporos Int 1(Suppl):204-205.
12. Slovik D M, Rosenthal DI, Doppelt SH, Potts JT Jr, Daly MA, Campbell JA, Neer RM 1986 Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25 dihydroxyvitamin D. J Bone Miner Res 1:377-381.
13. Lane NE, Sanchez S, Modin G, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse steroid osteoporosis: Results of a randomized clinical trial. J Clin Invest 102:1627-1633.
14. Parsons JA, Reit B, Robinson CJ 1973 A chick bioassay for parathyroid hormone. Endocrinology 92:454-462.
15. Singer FR, Aldred JP, Neer RM, Krane SM, Potts JT Jr, Bloch KJ 1972 An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331-2338.
16. Black DM, Palermo L, Nevitt MC, Genant HK, Epstein R, San Valentin R, Cummings, SR 1995 Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures. J Bone Miner Res 10:890-902.
17. Black D M, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt M, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541.
18. 1990 BMDP Statistical Software Manual. Dixon WJ (chief ed.) University of California Press, Berkeley, CA, U.S.A., pp. 197-200.
19. Gohel A, and Gronowicz G 1997 Glucocorticoid induce apoptosis in osteoblasts in mice by the regulation of BCL-2 and other cell cycle factors. J Bone Miner Res 12(Suppl 1):S284.
20. Weinstein RS, Jilka RL, Parfitt M, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoid. J Clin Invest 102:274-282.
21. Saag, K, Emkey R, Cividino, Brown J, Goemaere S, Dumortier T, Diafotis A, Czachur M, for the alendronate study group 1998 Effects of alendronate for two years on bone mineral density and fractures in patients receiving glucocorticoid. Bone 23(Suppl 1):S182, 1141.
22. Pitt P, Li F, Todd P, Webber D, Pack S, Moniz C 1998 A double-blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral glucocorticoid treatment. Thorax 53:351-356.
23. Finkelstein JS, Arnold AL 1999 Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J Clinical Endocrinol Metab 84:1214-1220.
24. Lukert, BP, Johnson, BE, Robinson, RG 1992 Estrogen and progesterone replacement reduces glucocorticoid-bone loss. J Bone Miner Res 7:1063-1069.